Key facts
- Enveda’s last known valuation is $1.2B (Sep 2025).
- It has raised $530.0M; the latest was Later Stage VC ($150.0M) in Sep 2025.
- Notable investors include Gaingels, Lux Capital, Village Global, True Ventures, Kevin Moore — 41 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 41 names
- ·Watchlist + deal alerts for Enveda
- ·The full record, as it builds
Funding rounds
No funding rounds for Enveda are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Enveda
Developer of a drug analysis platform designed to capitalize on the chemical diversity and evolutionary significance of natural samples. The company's platform offers a combination of machine learning, metabolomics, and robotics to analyze natural samples for both chemical structure and biological activity, enabling clients in the healthcare industry to identify and characterize a wide range of molecules produced by living organisms without isolating individual compounds or conducting extensive experimentation.
- Sector
- Healthcare
- HQ
- Boulder, CO, United States
- Founded
- 2019
- Employees
- 325
- Website
- enveda.com/
- Ownership
- Privately Held (backing)
Enveda doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Enveda shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Enveda in its N-PORT filings yet. We sweep new filings monthly.